Weekly Market Recap: TRex Bio, Retension and Anthropic's Roadshow Timeline — Week of October 5

A quiet start to the fourth quarter for the US IPO market: two small biotechs priced on Friday, October 9, a SPAC priced earlier in the week, and several deals were cut back or delayed. The bigger story sits just off the calendar — Anthropic is reportedly preparing to begin formal IPO marketing as early as the week of November 9. Below we separate what is confirmed from what is reported or estimated. For the full list of deals, see our IPO Calendar.

This Week's Debuts

• TRex Bio (TRXB, Nasdaq): priced at $14 per share, the low end of its $14–$16 range, for an 8.3M-share deal of roughly $117M. The autoimmune-focused biotech planned to use proceeds mainly for Phase 2 trials of its lead candidate TRB-061. Trading was scheduled to begin October 9; first-day performance was not yet available when this was written.
• Retension Pharmaceuticals (RTSN, Nasdaq): priced at $12, the midpoint of its $11–$13 range. The base deal of 3.3M shares is roughly $40M (IPOScoop lists about $45M, which appears to include the over-allotment option). The hypertension drug developer plans a Phase 2b study of its lead candidate. Trading was scheduled to begin October 9; first-day performance was not yet available at writing.
• Pine Tree Acquisition (SPAC): priced a $100M blank-check IPO on October 6, according to Renaissance Capital. This follows Southport Acquisition II's $200M AI-focused SPAC on October 1.

Fact vs. estimate: Prices, share counts and dates above come from IPOScoop, Renaissance Capital and company filings and are treated as confirmed. Deal sizes are approximations (they depend on whether the over-allotment option is counted), and no first-day closing prices are included because they were not available at publication. Our commentary on what this means for the market is an estimate, not a forecast of returns.

Market Tone: Selective, With Cutbacks

Renaissance Capital's third-quarter review counted 30 US listings raising $32.8B, but $26.5B of that was a single deal (SK hynix); excluding it, proceeds were $6.2B. It cited AI-spending concerns, a 19-year high in bond yields and resumed rate hikes as headwinds. That tone carried into October: Amaero cut its planned offering by about 60% to roughly $20M, the SPAC Calm Seas reduced its deal by 25%, and Renaissance noted that last week's larger IPO, Accelevation, was trading down. Risk: weak after-market trading makes issuers more likely to postpone or downsize. Opportunity: disciplined pricing can leave room for healthier aftermarket performance and more reasonable entry valuations.

Pre-IPO Spotlight: Anthropic's Reported Roadshow Timeline

Bloomberg reported on October 1 (as relayed by Renaissance Capital and Implicator) that Anthropic could start formal IPO marketing as soon as the week of November 9, which would put a debut before Thanksgiving (November 26). Anthropic is also said to have invited institutional investors to an investor day at its San Francisco headquarters on October 14. The company submitted a confidential draft registration statement in June, and its May private funding round valued it at $965B. Reports say prospective investors regard a $1.8–$2 trillion valuation as fair, and that the company hopes to raise as much as or more than SpaceX's record $75B IPO in June.

What is confirmed vs. reported: the confidential filing and the May round are company-disclosed facts. The roadshow date, valuation range and raise size are based on unnamed sources, no public prospectus exists yet, and the schedule could change. A November 9 start would require a public S-1 filing in late October.

Opportunity: a successful listing would be a landmark price-discovery event for AI-related private assets. Risk: a very large offering at a high valuation, in a market already worried about AI spending and rising yields, may meet pushback on price or timing.

What's Ahead Next Week

• Iambic Therapeutics (IAM): biotech targeting about $150M (9.4M shares at $15–$17), expected Thursday, October 15, led by J.P. Morgan, Jefferies, BofA Securities and Citigroup (IPOScoop).
• Anthropic investor day on October 14 (reported).
• Further out: Bitari (BIAI) and Web3Labs Global (MDAT) are expected the week of October 19, followed by BW Industrial Holdings (BWGC) and Primagrove (YNTE) the week of October 26 — all small deals of roughly $17–$31M. Lycia Therapeutics, Centinel Spine (each about $100M) and DayOne Data Centers (about $3.0B) have filed and are not yet scheduled.

The full table is on our IPO Calendar page.

Why It Matters for Pre-IPO and Tokenized Equity Investors

Public IPO pricing is the benchmark that private-market holdings are ultimately measured against. Small, modestly priced biotech deals show that the window is open but selective, while a potential trillion-dollar AI listing in November could either reopen the door for other late-stage private companies or absorb investor capital and attention. For holders of secondary Pre-IPO positions and tokenized equity products tied to these names, the main risks are valuation resets, lock-up expirations, thin liquidity and structural issues around custody and legal rights; the main opportunity is a clearer exit path if public demand holds. All views on market direction above are our estimates, not predictions.

This material is for informational purposes only and does not constitute individual investment advice.

Sources

• Renaissance Capital — US IPO Week Ahead: Quiet start for the 4Q IPO market as Anthropic looms
• Renaissance Capital — IPO News
• Renaissance Capital — 3Q 2026 US IPO Market Review
• IPOScoop — IPO Calendar
• Fierce Biotech — TRex Bio, Retension and Lycia gear up to go public
• Implicator — Anthropic could start IPO roadshow week of Nov. 9
• The Next Web — Anthropic is targeting an IPO the size of the largest ever